AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04218240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 200 MG capsules
Description: oral pregabalin 200 mg capsules given with a taper on day 5
Study NCT04218240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: oral Placebo
Study NCT04218240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine 0.18Mg Tab
Description: lofexidine 0.18 tab given with a taper starting on day 5
Study NCT04218240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.18Mg Tab
Description: lofexidine 0.18 tab given with a taper starting on day 5
Study NCT02435212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox granule formulation
Description: Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
Study NCT02435212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox DT formulation
Description: Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
Study NCT03085043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT03085043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT of the abdomen and pelvis
Study NCT03085043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo pelvic MRI
Study NCT03085043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Whole Body Diffusion-Weighted Imaging
Description: Undergo magnetic resonance whole body diffusion-weighted imaging
Study NCT04984551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension of Community Health (ECHO) Telementoring Clinic
Description: Participate in ECHO clinics presenting cases for guidance and feedback
Study NCT04984551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Country Workshops
Description: In-Country Workshops Participate in hands-on training and workshops
Study NCT04984551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional Oncology Educations Programs
Description: Receive 5 core online lectures
Study NCT04984551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Medical charts are reviewed for data collection
Study NCT04984551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire(s)
Study NCT01379898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
Study NCT01379898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
Study NCT02839096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
Study NCT02839096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
Study NCT02623972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: administered IV for 4 cycles
Study NCT02623972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: administered IV with cyclophosphamide for 4 cycles
Study NCT02623972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administered IV with adriamycin for 4 cycles
Study NCT04245150 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Stool sample
Study NCT04245150 — intervention group
Intervention type: OTHER
Intervention: Skin Swab Sample
Description: Skin Swab Sample
Study NCT03450161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl dosing schemes
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
Study NCT02608190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: See protocol
Study NCT02608190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working memory training
Description: See protocol
Study NCT01783613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months
Study NCT01783613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 50 mg/kg/day during 12 months
Study NCT01283139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 200 mg
Description: Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Study NCT01283139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 600 mg
Description: Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Study NCT01283139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 1,200 mg
Description: Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
Study NCT01283139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
Study NCT00004563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
Study NCT00004563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching gelcaps 25 mgs
Study NCT01423500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16
Description: patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
Study NCT01423500 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
Study NCT01423500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16, ATG
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
Study NCT01423500 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
Study NCT02614417 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
Study NCT04441060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distress intervention (CBT & Mindfulness-based program)
Description: Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
Study NCT02862834 — intervention group
Intervention type: GENETIC
Intervention: High-throughput exome sequencing
Study NCT06434896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA analysis after surgery
Description: ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
Study NCT04901260 — intervention group
Intervention type: DEVICE
Intervention: AMAZE™ Disease Management Platform
Description: The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
Study NCT04656704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase injected intradermally
Description: Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
Study NCT04572113 — intervention group
Intervention type: DEVICE
Intervention: Cervical collar
Description: Data will be recorded while patients are not wearing or wearing one of two cervical collars
Study NCT00318071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merci Retriever
Description: For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography.
Study NCT02744911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeechVive device
Description: The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
Study NCT02744911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeechVive device
Description: The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
Study NCT02744911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine interaction
Description: Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
Study NCT02744911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In person interaction
Description: Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
Study NCT04641871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study NCT04641871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study NCT04641871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study NCT04641871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Study NCT02013960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec
Description: Cytotec medication compared with cytotec and laminaria
Study NCT02013960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotec
Description: Cytotec medication compared with cytotec and laminaria
Study NCT03989518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear acquisition
Description: Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
Study NCT03989518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal extinction
Description: Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
Study NCT03989518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinstatement
Description: Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
Study NCT03983603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)
Description: Soft chews containing 0.5g plant stanols delivered as plant stanol esters
Study NCT03983603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft chew
Description: Soft chew that does not contain plant stanols
Study NCT02729285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
Study NCT02729285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
Study NCT02729285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scleral buckle
Description: Surgical procedure of scleral buckle under retrobulbar block anesthesia
Study NCT02729285 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scleral buckle
Description: Surgical procedure of scleral buckle under retrobulbar block anesthesia
Study NCT00950326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
Study NCT01423500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, OKT3, Treosulfan, Thiotepa
Description: patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
Study NCT01423500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16, ATG
Description: patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
Study NCT01423500 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
Study NCT05322798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency SCS
Description: Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
Study NCT05322798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency SCS
Description: Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
Study NCT03138369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular nerve stimulator
Description: Battery powered headset that can be recharged when not being used.
Study NCT03138369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vestibular stimulation
Description: Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
Study NCT00950326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Affusion
Description: Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
Study NCT00950326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Affusion/ Physiotherapy
Description: Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
Study NCT00797251 — intervention group
Intervention type: PROCEDURE
Intervention: Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.
Description: The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
Study NCT00690560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00690560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00690560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00690560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00690560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00690560 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT04238273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Echocardiography
Description: Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
Study NCT05672758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sprint training
Description: One-year cycle including specific sprint-oriented athletic training
Study NCT05672758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Endurance training
Description: One-year cycle including specific endurance-oriented athletic training
Study NCT05672758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Recreational Training
Description: One year of nonspecific recreational training
Study NCT04716764 — intervention group
Intervention type: OTHER
Intervention: 3-Day Food Intake Record
Description: Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
Study NCT02379104 — intervention group
Intervention type: DEVICE
Intervention: ROTEM sigma
Description: Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
Study NCT02951767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
Study NCT01237587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT01237587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Administered orally
Study NCT01237587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally